Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | +2.41% | -10.05% | +6.25% |
May. 16 | Reneo Pharmaceuticals Insider Bought Shares Worth $639,578, According to a Recent SEC Filing | MT |
May. 13 | Reneo Pharmaceuticals to Merge With OnKure in All-Stock Deal -- Reneo Shares Rise | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 55.48M |
---|---|---|---|---|---|
Net income 2024 * | -22M | Net income 2025 * | -23M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.55
x | P/E ratio 2025 * |
-2.41
x | Employees | 8 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.86% |
1 day | -4.05% | ||
1 week | -12.63% | ||
Current month | -0.60% | ||
1 month | -0.60% | ||
6 months | -71.86% | ||
Current year | +3.75% |
Managers | Title | Age | Since |
---|---|---|---|
Niall O'Donnell
FOU | Founder | 51 | - |
Gregory Flesher
CEO | Chief Executive Officer | 54 | 20-12-08 |
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Grey
FOU | Founder | 71 | 14-09-21 |
Director/Board Member | 64 | 17-11-30 | |
Paul Hoelscher
BRD | Director/Board Member | 59 | 22-01-19 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.49% | 4 M€ | -5.15% | - | |
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.7 | +2.41% | 119 685 |
24-05-24 | 1.66 | -4.05% | 135,156 |
24-05-23 | 1.73 | -5.46% | 138,155 |
24-05-22 | 1.83 | -3.17% | 121,389 |
24-05-21 | 1.89 | -0.53% | 100,069 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.75% | 55.48M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+42.32% | 40.47B | |
-10.02% | 27.17B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- RPHM Stock